-
Aldeyra Secures US Orphan Drug Tag For Its Retinitis Pigmentosa Candidate
Wednesday, August 4, 2021 - 11:23am | 150Read More...The FDA has granted orphan drug designation to Aldeyra Therapeutics Inc's (NASDAQ: ALDX) ADX-2191 to treat retinitis pigmentosa (RP). ADX-2191 is a methotrexate for intravitreal injection. Methotrexate inhibits dihydrofolic reductase, an enzyme involved in cellular...
-
Ocugen's Vision Loss Gene Therapy Receives Orphan Drug Tag In Europe
Tuesday, February 23, 2021 - 10:29am | 203Read More...The European Commission has designated Orphan Medicinal Product status to Ocugen Inc's (NASDAQ: OCGN) OCU400 (AAV5-hNR2E3) to treat both retinitis pigmentosa (RP) and Leber Congenital amaurosis (LCA). Orphan medicinal product benefits include protocol assistance,...
-
Second Sight Medical Just Had Another Big Day...And More Headlines Could Be Coming
Tuesday, June 23, 2015 - 5:01pm | 436Read More...Second Sight Medical Products Inc (NASDAQ: EYES) shares were up sharply in early trading Tuesday after the company reported positive clinical trial results from a three-year multi center study post-implant of its Argus II Retinal Prosthesis System. The stock closed at $16.28, up 3.1 percent on...
